Phaedra Chrousos - 16 Jun 2022 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role: Director
Signature: /s/ Phaedra Chrousos
Issuer symbol: VNDA
Transactions as of: 16 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 21 Jun 2022, 16:53:48 UTC
Previous filing: 15 Jun 2021
Next filing: 12 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VNDA	Common Stock	Award	$0	+12,006	+93%	$0.000000	24,931	16 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VNDA	Stock Option (Right to Buy)	Award	$0	+24,707		$0.000000	24,707	16 Jun 2022	Common Stock	24,707	$9.37	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
F2	This option vests and becomes exercisable with respect to 100% of the option shares on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.